A detailed history of Vanguard Group Inc transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,786,334 shares of SLS stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,786,334
Previous 1,513,235 18.05%
Holding current value
$2.11 Million
Previous $1.53 Million 39.07%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.06 - $1.63 $289,484 - $445,151
273,099 Added 18.05%
1,786,334 $2.13 Million
Q1 2024

May 10, 2024

BUY
$0.51 - $1.55 $186,614 - $567,162
365,911 Added 31.89%
1,513,235 $1.53 Million
Q4 2023

Feb 14, 2024

BUY
$0.88 - $1.57 $97,167 - $173,356
110,418 Added 10.65%
1,147,324 $1.22 Million
Q3 2023

Nov 14, 2023

BUY
$1.42 - $1.83 $128,081 - $165,062
90,198 Added 9.53%
1,036,906 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$1.35 - $1.8 $67,224 - $89,632
49,796 Added 5.55%
946,708 $1.49 Million
Q1 2023

May 15, 2023

BUY
$1.18 - $3.86 $48,177 - $157,596
40,828 Added 4.77%
896,912 $1.28 Million
Q4 2022

Feb 10, 2023

BUY
$1.8 - $5.41 $46,737 - $140,470
25,965 Added 3.13%
856,084 $2.02 Million
Q2 2022

Aug 12, 2022

BUY
$2.14 - $4.15 $370,648 - $718,780
173,200 Added 26.37%
830,119 $1.85 Million
Q1 2022

May 13, 2022

BUY
$4.73 - $7.18 $11,148 - $16,923
2,357 Added 0.36%
656,919 $4.39 Million
Q4 2021

Feb 14, 2022

BUY
$5.36 - $9.53 $17,575 - $31,248
3,279 Added 0.5%
654,562 $3.62 Million
Q3 2021

Nov 12, 2021

BUY
$8.21 - $10.53 $268,869 - $344,846
32,749 Added 5.29%
651,283 $5.97 Million
Q2 2021

Aug 13, 2021

BUY
$7.19 - $13.71 $4.45 Million - $8.48 Million
618,534 New
618,534 $6.87 Million

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $24.3M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.